[go: up one dir, main page]

WO2015022560A8 - Stable pharmaceutical composition containing bisoprolol and ramipril - Google Patents

Stable pharmaceutical composition containing bisoprolol and ramipril Download PDF

Info

Publication number
WO2015022560A8
WO2015022560A8 PCT/HU2014/000072 HU2014000072W WO2015022560A8 WO 2015022560 A8 WO2015022560 A8 WO 2015022560A8 HU 2014000072 W HU2014000072 W HU 2014000072W WO 2015022560 A8 WO2015022560 A8 WO 2015022560A8
Authority
WO
WIPO (PCT)
Prior art keywords
ramipril
composition containing
pharmaceutical composition
stable pharmaceutical
containing bisoprolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2014/000072
Other languages
French (fr)
Other versions
WO2015022560A1 (en
Inventor
Éva GUTINÉ MOLNÁR
Zsolt Zsigmond
Zoltánné TÓTH
Ádám ORBÁN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Priority to EA201690395A priority Critical patent/EA033291B1/en
Priority to HU1600414A priority patent/HU231052B1/en
Publication of WO2015022560A1 publication Critical patent/WO2015022560A1/en
Publication of WO2015022560A8 publication Critical patent/WO2015022560A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a combination composition containing ramipril and bisoprolol and preparation thereof. The active ingredients are separated from each other in the composition.
PCT/HU2014/000072 2013-08-16 2014-08-15 Stable pharmaceutical composition containing bisoprolol and ramipril Ceased WO2015022560A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA201690395A EA033291B1 (en) 2013-08-16 2014-08-15 Dosage unit comprising ramipril and bisoprolol hemifumarate, process for the preparation thereof and method of treating hypertension
HU1600414A HU231052B1 (en) 2013-08-16 2014-08-15 Stable pharmaceutical composition containing bisoprolol and ramipril

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1300496 2013-08-16
HU1300496A HUP1300496A2 (en) 2013-08-16 2013-08-16 Stable pharmaceutical composition

Publications (2)

Publication Number Publication Date
WO2015022560A1 WO2015022560A1 (en) 2015-02-19
WO2015022560A8 true WO2015022560A8 (en) 2015-05-14

Family

ID=89991232

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/HU2014/000071 Ceased WO2015022559A1 (en) 2013-08-16 2014-08-15 Pharmaceutical composition containing rosuvastatin and ramipril
PCT/HU2014/000072 Ceased WO2015022560A1 (en) 2013-08-16 2014-08-15 Stable pharmaceutical composition containing bisoprolol and ramipril

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/HU2014/000071 Ceased WO2015022559A1 (en) 2013-08-16 2014-08-15 Pharmaceutical composition containing rosuvastatin and ramipril

Country Status (3)

Country Link
EA (1) EA033291B1 (en)
HU (2) HUP1300496A2 (en)
WO (2) WO2015022559A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501502A1 (en) * 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
EP4106733A2 (en) 2020-02-10 2022-12-28 Adamed Pharma S.A. Stable ramipril composition and fixed dose composition comprising thereof
CN115068434B (en) * 2022-08-03 2023-05-09 昆山龙灯瑞迪制药有限公司 Preparation method of ramipril tablet

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88621I2 (en) 1980-10-23 1995-09-01 Schering Corp Sandopril
DE3226768A1 (en) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF
DE3739690A1 (en) 1987-11-24 1989-06-08 Hoechst Ag STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS
US20030215526A1 (en) 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
EP1501546B1 (en) * 2002-05-03 2012-10-10 Hexal AG Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
PL1635792T3 (en) 2003-06-26 2009-08-31 Teva Pharmaceutical Industries Ltd Stable pharmaceutical compositions of 2-aza-bicyclo¬3.3.0 -octane-3-carboxylic acid derivatives
EP1694308A1 (en) 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2394660A (en) 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
EA011862B1 (en) 2004-03-24 2009-06-30 Актавис Груп Хф. Formulations of ramipril
CA2586547A1 (en) * 2004-11-05 2006-05-11 King Pharmaceuticals Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods
WO2007056442A1 (en) * 2005-11-07 2007-05-18 King Pharmaceuticals Research & Development, Inc. Compositions of stabilized ramipril in combination with another active agent
CN100374462C (en) 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 Truncated glucagon-like peptide 1 (sGLP-1), preparation method and application
US20070232680A1 (en) 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
MX2008013374A (en) 2006-04-19 2008-11-12 Teva Pharma Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane -3-carboxylic acid derivatives.
US20100035955A1 (en) 2006-06-30 2010-02-11 Panagiotis Keramidas Stabilised Composition Comprising ACE Inhibitors
EP2049089A4 (en) 2006-08-08 2012-07-04 Accu Break Technologies Inc Pharmaceutical tablets containing a plurality of active segments
WO2008065485A2 (en) 2006-10-19 2008-06-05 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor
WO2008095263A1 (en) 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2008132756A1 (en) 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
HU230877B1 (en) 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable combination medicine
EP2272874A1 (en) 2009-07-10 2011-01-12 CSL Behring GmbH Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation
CN101612403A (en) 2009-08-13 2009-12-30 王丽燕 The pharmaceutical composition that contains calcium antagonist, ACE inhibitor and statins
EP3501501A1 (en) 2012-02-17 2019-06-26 Egis Gyógyszergyár Zrt. Pharmaceutical formulation having improved stability

Also Published As

Publication number Publication date
HUP1300496A2 (en) 2015-03-02
WO2015022559A1 (en) 2015-02-19
EA201690395A1 (en) 2016-07-29
WO2015022560A1 (en) 2015-02-19
EA033291B1 (en) 2019-09-30
HU231052B1 (en) 2020-02-28
HUP1600414A2 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
IL285390A (en) Arylquinazolines, their preparation and pharmaceutical compositions containing them
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
IL235767A (en) Substituted pyrrolidines, pharmaceutical compositions comprising the same and uses thereof
HK1213779A1 (en) Composition for immediate and extended release
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
EP3067059A4 (en) Pharmaceutical composition for preventing or treating thyroid diseases, containing lonicera caerulea l. var. edulis fruit extract as active ingredient
PH12014502856A1 (en) Solid pharmaceutical preparation containing levothyroxine
WO2014179567A3 (en) Methods and compositions for treating beta-thalassemia and sickle cell disease
IL233825A (en) 1h-indazole-3-carboxamide compounds, compositions comprising them and uses thereof in the preparation of medicaments
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
IL233602A (en) Benzamide derivatives, their preparation and pharmaceutical compositions containing them
WO2015092810A3 (en) Amorphous form of idelalisib
MX363699B (en) Co-micronisation product comprising ulipristal acetate.
IL280376A (en) Boronic acid derivatives, their preparation and pharmaceutical compositions containing them
IL272806B1 (en) Boronic acid derivatives, their preparation and pharmaceutical compositions containing them
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EP3068436A4 (en) Topical pharmaceutical, cosmetic and disinfectant compositions comprising phosphatidylcholine
MX357704B (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
WO2012093973A3 (en) Compositions in the form of tablets comprising acarbose
WO2014133811A3 (en) Compounds from invasive salvinias and methods of using the same
WO2015022560A8 (en) Stable pharmaceutical composition containing bisoprolol and ramipril
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines
MX2014006201A (en) Imatinib solid dosage forms reconstituted just before use.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14777376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201690395

Country of ref document: EA

122 Ep: pct application non-entry in european phase

Ref document number: 14777376

Country of ref document: EP

Kind code of ref document: A1